Efalizumab for Severe Palmo-plantar Psoriasis: an Open-label Pilot Trial in Five Patients

Background: Palmo-plantar psoriasis (PPP) is a disabling condition that significantly impairs quality of life. PPP tends to be resistant to conventional therapies and may last for several years. Topical treatments are usually ineffective. Systemic therapy with oral retinoids and psoralen plus ultraviolet A is frequently required, although it rarely leads to remission.

Study Design: We conducted an open-label, pilot study to evaluate treatment of PPP with efalizumab, an anti-CD11a monoclonal antibody approved for the treatment of chronic, refractory moderate to severe plaque psoriasis in adults.

Methods: Five patients with severe PPP received efalizumab treatment for 24 weeks.

Results: All five patients responded favourably by week 12 and showed further improvement at week 24 of uninterrupted therapy. Mean physician-assessed severity scores and patient-reported outcome scores improved almost 75% after 12 weeks and 90% after 24 weeks. At week 32, three patients maintained the response seen at week 24, while two patients suspended efalizumab.

Conclusions: Efalizumab therapy was well tolerated and effective in five patients with severe PPP, allowing a significant improvement in quality of life.